Picture of ABion logo

203400 ABion Share Price

0.000.00%
kr flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m+10.66%
3m+0.94%
6m-11.46%
1yr-1.56%
Volume Change (%)
10d/3m+53.32%
Price vs... (%)
52w High-46.77%
50d MA+8.95%
200d MA-7.84%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-111.01%
Return on Equity-227.67%
Operating Margin-4484.2%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of ABion EPS forecast chart

Profile Summary

ABION Inc. is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics.

Directors

Last Annual
December 31st, 2024
Last Interim
December 31st, 2024
Incorporated
April 16th, 2007
Public Since
July 21st, 2014
No. of Shareholders
13,490
No. of Employees
24
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
kr flag iconKorea Exchange - KOSDAQ
Shares in Issue
28,637,415

203400 Share Price Performance

Upcoming Events for 203400

Similar to 203400

Picture of 3Billion logo

3Billion

kr flag iconKorea Exchange - KOSDAQ

Picture of ABL Bio logo

ABL Bio

kr flag iconKorea Exchange - KOSDAQ

Picture of Amicogen logo

Amicogen

kr flag iconKorea Exchange - KOSDAQ

Picture of AprilBio Co logo

AprilBio Co

kr flag iconKorea Exchange - KOSDAQ

Picture of AptaBio Therapeutics logo

AptaBio Therapeutics

kr flag iconKorea Exchange - KOSDAQ

FAQ

0